"The roll-out of breakthroughs in the United States has conventionally followed the 'linear' framework laid out in science adviser Vannevar Bush's 1945 report. This model has catalysed decades of economic and technological gains, but the private sector's growing emphasis on reducing risk and maximizing returns is distorting research priorities."
"In 2022, more than half of US Food and Drug Administration (FDA) approvals of new drugs were for those targeting cancer and rare diseases. Such areas generate high revenues because drug prices are high, and people are willing to pay for the latest treatments."
For 80 years, federally supported research in the U.S. has driven advancements in various fields, including biomedicine. Innovations have led to significant improvements in health, such as vaccines and cancer treatments. However, the current pace of innovation and societal challenges necessitate a reevaluation of research investment priorities. The traditional linear model of research funding is becoming inadequate as private sector interests skew focus towards profitable diseases, often neglecting others. New technologies like AI and big data offer opportunities for more effective health interventions and personalized medicine.
Read at Nature
Unable to calculate read time
Collection
[
|
...
]